Holen Sie sich die Stockscreener-App
4.45
0.91%
0.04
Handel nachbörslich:
4.53
0.08
+1.80%
Schlusskurs vom Vortag:
$4.41
Offen:
$4.53
24-Stunden-Volumen:
3.08M
Relative Volume:
0.59
Marktkapitalisierung:
$1.55B
Einnahmen:
$62.90M
Nettoeinkommen (Verlust:
$-204.63M
KGV:
-7.4204
EPS:
-0.5997
Netto-Cashflow:
$-181.78M
1W Leistung:
+9.88%
1M Leistung:
-3.05%
6M Leistung:
+18.04%
1J Leistung:
+168.07%
1-Tages-Spanne:
$4.435
$4.6482
1-Wochen-Bereich:
$4.12
$4.6482
52-Wochen-Spanne:
$1.54
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Firmenname
Nuvation Bio Inc
Sektor
Branche
Telefon
332-208-6102
Adresse
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
4.45 | 1.53B | 62.90M | -204.63M | -181.78M | -0.5997 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-19 | Eingeleitet | B. Riley Securities | Buy |
| 2025-09-30 | Eingeleitet | Jefferies | Buy |
| 2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-03-27 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-26 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-01-06 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-03-08 | Eingeleitet | BTIG Research | Buy |
| 2021-03-08 | Eingeleitet | Cowen | Outperform |
| 2021-03-08 | Eingeleitet | Jefferies | Buy |
| 2021-03-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Nuvation Bio Inc Aktie (NUVB) Neueste Nachrichten
Nuvation Bio Inc. (NUVB) Turns Bullish amid Positive Regulatory Trajectory in Europe - Yahoo Finance Singapore
[144] Nuvation Bio Inc. SEC Filing - stocktitan.net
RBC Capital raises Nuvation Bio stock price target on glioma potential - Investing.com
RBC Raises Price Target on Nuvation Bio to $20 From $13, Keeps Outperform, Speculative Risk - marketscreener.com
JPMorgan Chase & Co. Purchases 557,656 Shares of Nuvation Bio Inc. $NUVB - marketbeat.com
Capricorn Fund Managers Ltd Makes New Investment in Nuvation Bio Inc. $NUVB - marketbeat.com
Nuvation Bio gains global rights to brain cancer therapy from Daiichi Sankyo - MSN
2026-04-05 | Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NYSE:NUVB | Press Release - Stockhouse
Nuvation Bio Inc. (NUVB): Billionaire David Abrams has a long-term bet on this stock - MSN
10 Best Multibagger Penny Stocks to Invest In - Insider Monkey
Aug Reactions: Is Nuvation Bio Inc exposed to currency risks2026 Price Momentum & Daily Profit Focused Stock Screening - baoquankhu1.vn
Is EMA Validation Of Taletrectinib Expanding Nuvation Bio’s (NUVB) Targeted Lung Cancer Opportunity? - Sahm
Bullish analyst sentiment on Nuvation Bio (NUVB) amid early commercialization progress - MSN
2026-04-03 | Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc. (NUVB) Shareholders to Inquire about Securities Investigation | NYSE:NUVB | Press Release - Stockhouse
Nuvation Bio Inc. (NUVB) amends protocol on safusidenib trials in astrocytoma - MSN
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact L - GuruFocus
Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nuvation Bio Inc. (NUVB) And Encourages Investors to Connect - ACCESS Newswire
Nuvation Bio (NYSE:NUVB) Earns "Outperform" Rating from Wedbush - marketbeat.com
Nuvation Bio secures global rights to safusidenib from Daiichi Sankyo By Investing.com - Investing.com South Africa
NUVB Stock Price, Quote & Chart | NUVATION BIO INC (NYSE:NUVB) - ChartMill
Truist reiterates Buy on Nuvation Bio stock, $12 target on Japan deal By Investing.com - Investing.com South Africa
Truist reiterates Buy on Nuvation Bio stock, $12 target on Japan deal - Investing.com Australia
Nuvation Bio announces acquisition of Japan rights to safusidenib from Daiichi Sankyo - MarketScreener
Nuvation Bio Announces Acquisition Of Japan Rights To Safusidenib From Daiichi Sankyo - TradingView
Nuvation gains global rights to brain cancer drug (NUVB:NYSE) - Seeking Alpha
Nuvation Bio secures global rights to safusidenib from Daiichi Sankyo - Investing.com
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo - PR Newswire
Nuvation Bio Inc. (NUVB) and Eisai Get EMA Validation for Taletrectinib - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc. (NUVB) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
5 Best Stocks Under $10 to Buy and Hold Forever - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nuvation Bio Inc. (NUVB) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
A Look At Nuvation Bio’s Valuation As EMA Validates Taletrectinib Application In Europe - Sahm
Nuvation Bio, Eisai application for taletrectinib for NSCLC accepted by EMA - MSN
Eisai And Nuvation Bio Advance Taletrectinib With EMA Validation For ROS1 Positive Lung Cancer - BioPharma APAC
Profit Review: Can Nuvation Bio Inc sustain earnings growth2026 Institutional & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Nuvation Bio outlines first-line IBTROZI growth strategy with 50-month median DOR amid expanding global partnerships - MSN
H.C. Wainwright reiterates Nuvation Bio stock rating on EU filing By Investing.com - Investing.com India
Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Wedbush Reiterates Outperform Rating for Nuvation Bio (NYSE:NUVB) - MarketBeat
H.C. Wainwright reiterates Nuvation Bio stock rating on EU filing - Investing.com
H.C. Wainwright Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $17 - Moomoo
March 2026's Promising Penny Stocks To Watch - simplywall.st
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency - JCN Newswire
Nuvation Bio Inc. (NUVB): Billionaire David Abrams Has a Long-Term Bet on This Stock - Yahoo Finance
Finanzdaten der Nuvation Bio Inc-Aktie (NUVB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvation Bio Inc-Aktie (NUVB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Liu Dongfang | CHIEF MEDICAL OFFICER |
Dec 01 '25 |
Option Exercise |
2.93 |
150,000 |
439,500 |
168,000 |
| Liu Dongfang | CHIEF MEDICAL OFFICER |
Dec 01 '25 |
Sale |
7.82 |
150,000 |
1,173,255 |
18,000 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):